As PSA Tests Drop, Adv. Prostate Cancer Cases Rise

New research suggests that recommendations against routine prostate cancer testing may have come at a steep price -- more men getting diagnosed with advanced prostate cancers.
Source: WebMD Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 24 May 2020Source: European UrologyAuthor(s): Amar U. Kishan, Tahmineh Romero, Mohammed Alshalalfa, Yang Liu, Phuoc T. Tran, Nicholas G. Nickols, Huihui Ye, Dipti Sajed, Matthew B. Rettig, Robert E. Reiter, Isla P. Garraway, Daniel E. Spratt, Steven J. Freedland, Xin Zhao, Ziwen Li, Matthew Deek, Julie Livingstone, Brandon A. Mahal, Paul L. Nguyen, Felix Y. Feng
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conditions:   Prostate Cancer;   Radical Prostatectomy Intervention:   Combination Product: Microdevice Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Despite the emphasis on randomized data to guide evidence-based practice, there is a notable lack of clinical trials to inform comparative effectiveness in surgical disciplines. Although this is multifactorial in nature, this paucity ultimately reflects the difficulty associated with conducting surgical trials, particularly in settings where event rates are low (eg, lymph node metastasis in M0 renal cell carcinoma) or when long follow-up is required, as with early-stage disease (eg, low-risk prostate cancer).
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
o-Hong Chen Enzalutamide is the first second-generation nonsteroidal androgen receptor (AR) antagonist with a strong binding affinity to AR. Most significantly, enzalutamide can prolong not only overall survival time and metastatic free survival time for patients with lethal castration-resistant prostate cancer (CRPC), but also castration-resistant free survival time for patients with castration-sensitive prostate cancer (CSPC). Enzalutamide has thus been approved by the US Food and Drug Administration (FDA) for the treatment of both metastatic (in 2012) and non-metastatic (in 2018) CRPC, as well as CSPC (2019). This i...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
Publication date: Available online 22 May 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Giandomenico Roviello, Benedetta Panella
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 22 May 2020Source: European UrologyAuthor(s): Steven M. Monda, Marc Arnaldo Dall’Era
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 22 May 2020Source: European UrologyAuthor(s): Cameron Herberts, Andrew J. Murtha, Simon Fu, Gang Wang, Elena Schönlau, Hui Xue, Dong Lin, Anna Gleave, Steven Yip, Arkhjamil Angeles, Sebastien Hotte, Ben Tran, Scott North, Sinja Taavitsainen, Kevin Beja, Gillian Vandekerkhove, Elie Ritch, Evan Warner, Fred Saad, Nayyer Iqbal
Source: European Urology - Category: Urology & Nephrology Source Type: research
Authors: Holly JMP, Biernacka K, Perks CM Abstract Introduction: Preclinical, clinical, and population studies have provided robust evidence for an important role for the insulin-like growth factor (IGF) system in the development of prostate cancer.Areas covered: An overview of the IGF system is provided. The evidence implicating the IGF system in the development of prostate cancer is summarized. The compelling evidence culminated in a number of clinical trials of agents targeting the system; the reasons for the failure of these trials are discussed.Expert opinion: Clinical trials of agents targeting the IGF system...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Conditions:   Prostate Cancer;   Radical Prostatectomy Intervention:   Combination Product: Microdevice Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Health | Prostate Cancer